

BUKTI KORESPONDENSI
JURNAL NASIONAL TERAKREDITASI PERINGKAT 2

Judul artikel : In Silico Study of Compounds Identified in *Curcuma aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Jurnal : Journal of Food and Pharmaceutical Sciences (J. Food Pharm. Sci)

Edisi : Tahun 2025, Vol 13 No 2, hal 92-99


Penerbit : Integrated Research and Testing Laboratory, Universitas Gadjah Mada (LPPT-UGM)

Penulis : Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita

Tabel Tahapan Publikasi Artikel

No	Tahapan Publikasi	Tanggal	Halaman
1	Submission of manuscript	16 Mei 2025	2
2	Editor Decission	21 Mei 2025	3
3	Manuscript revision request	21 Mei 2025	5
4	Submit revised manuscript	22 Mei 2025	5
5	Acceptance Notification	2 Juni 2025	6
6	Payment Request	2 Juni 2025	7
7	Official payment receipt	12 Juni 2025	8
8	Copyediting Revision Request	18 Juni 2025	9
9	Send to Production	18 Juni 2025	10
10	Revised copyediting of Manuscript	19 Juni 2025	10
11	Article published Vol 13, No 2 (2025) https://jurnal.ugm.ac.id/v3/JFPS/article/view/21589/5920	30 Juni 2025	11
12	Lampiran bukti korespondensi	-	12-76

Pengusul



Dr. apt. Ririn Suharsanti, M.Sc

1. Submission of Manuscript

Journal of Food and Pharmaceutical Sciences | Tasks 1 | English | View Site | ririnsuharsanti

In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita

Submission | Review | Copyediting | **Production**

Submission Files

File ID	File Name	Date	Type
97952-1	ririnsuharsanti, JFPS_Ririn Suharsanti_16 Mei.docx	May 16, 2025	Article Text
97954-1	ririnsuharsanti, Hasil Turnitin_Ririn Suharsanti.pdf	May 16, 2025	Other
98042-1	astridesmayanti92, 21589-Blind.docx	May 17, 2025	Article Text

[Download All Files](#)

Pre-Review Discussions

Name	From	Last Reply	Replies	Closed
Comments for the Editor	ririnsuharsanti	-	0	<input type="checkbox"/>
	2025-05-16 11:56 AM			

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select | Threads | Options | Refresh

Reply | Reply all | Forward | Delete | Archive | Junk | Mark | More

[JFPS] Submission Acknowledgement

From Prof. Dr. Abdul Rohman, M.Si., Apt via Jurnal Ilmiah Universitas Gadjah Mada on 2025-05-16 12:11

Ririn Suharsanti:

Thank you for submitting the manuscript, "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer" to Journal of Food and Pharmaceutical Sciences. With the online journal management system that we are using, you will be able to track its progress through the editorial process by logging in to the journal web site:

Submission URL: <https://jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589>
Username: ririnsuharsanti

If you have any questions, please contact me. Thank you for considering this journal as a venue for your work.

Prof. Dr. Abdul Rohman, M.Si., Apt

Journal of Food and Pharmaceutical Sciences

2. Editorial Decision

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select Threads Options Refresh

Reply Reply all Forward Delete Archive Junk Mark More

Inbox Drafts Sent Junk Trash Archive

Search: jfps

- Astri Desmayanti via Jurna... Today 12:46
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:47
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:46
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-06-12 11:42
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:58
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:57
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-05-21 14:11
- [JFPS] Editor Decision
- Prof. Dr. Abdul Rohm... 2025-05-16 12:11
- [JFPS] Submission Acknowledgement

[JFPS] Editor Decision

From Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada on 2025-05-21 14:11

A-21589-Article Text-98044-1-4-20250517.docx (~1.9 MB)

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita:

We have reached a decision regarding your submission to Journal of Food and Pharmaceutical Sciences, "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Our decision is: Revisions Required

Astri Desmayanti
Universitas Gadjah Mada
desmayantiastri@gmail.com

Reviewer A:
Recommendation: Revisions Required

Title describes the content of papper properly and clearly

Good

Revelance of data and conclusion

Good

RECOMENDATION

Accepted with minor revision

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select Threads Options Refresh

Reply Reply all Forward Delete Archive Junk Mark More

Inbox Drafts Sent Junk Trash Archive

Search: jfps

- Astri Desmayanti via Jurna... Today 12:46
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:47
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:46
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-06-12 11:42
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:58
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:57
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-05-21 14:11
- [JFPS] Editor Decision
- Prof. Dr. Abdul Rohm... 2025-05-16 12:11
- [JFPS] Submission Acknowledgement

RECOMENDATION

Accepted with minor revision

Additional Comment

article revised according to feedback

Reviewer B:
Recommendation: Accept Submission

Title describes the content of papper properly and clearly

Good

Revelance of data and conclusion

Fair

RECOMENDATION

Accepted without revision

Additional Comment

over all the manuscript was good

English View Site

Submission Library

[JFPS] Editor Decision

2025-05-21 02:11 PM

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita:

We have reached a decision regarding your submission to Journal of Food and Pharmaceutical Sciences, "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Our decision is: Revisions Required

Astri Desmayanti
Universitas Gadjah Mada
desmayantiastri@gmail.com

Reviewer A:
Recommendation: Revisions Required

Title describes the content of papper properly and clearly
Good
Revelance of data and conclusion

English View Site

Submission Library

RECOMENDATION

Accepted with minor revision

Additional Comment

article revised according to feedback

Reviewer B:
Recommendation: Accept Submission

Title describes the content of papper properly and clearly
Good
Revelance of data and conclusion
Fair

RECOMENDATION

Accepted without revision

Additional Comment

3. Manuscript revision request

Journal of Food and Pharmaceutical Sciences | Tasks 1 | English | View Site | ririnsuharsanti

Submission Library | View Metadata

In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita

Submission | Review | Copyediting | Production

Round 1

Round 1 Status
Submission accepted.

Notifications

[JFPS] Editor Decision	2025-05-21 02:11 PM
[JFPS] Editor Decision	2025-06-02 06:57 PM
[JFPS] Editor Decision	2025-06-17 06:46 PM

Reviewer's Attachments [Search](#)

98490-1	, 21589-Article Text-98044-1-4-20250517.docx	May 21, 2025
---------	--	--------------

4. Submit revised manuscript

Journal of Food and Pharmaceutical Sciences | Tasks 1 | English | View Site | ririnsuharsanti

Reviewer's Attachments [Search](#)

98490-1	, 21589-Article Text-98044-1-4-20250517.docx	May 21, 2025
---------	--	--------------

Revisions [Search](#) [Upload File](#)

98587-1	Article Text, A-21589-Article Text-98044-1-4-20250517.docx	May 22, 2025	Article Text
---------	--	--------------	--------------

Review Discussions [Add discussion](#)

Name	From	Last Reply	Replies	Closed
No Items				

Platform & workflow by OJS / PKP

5. Acceptance Notification

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select Threads Options Refresh

Reply Reply all Forward Delete Archive Junk Mark More

[JFPS] Editor Decision

From Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada on 2025-06-02 18:57

C-LoA_Ririn Suharsanti.pdf (~407 KB)

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita:

We have reached a decision regarding your submission to Journal of Food and Pharmaceutical Sciences, "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Our decision is to: Accept Submission

Astri Desmayanti
Universitas Gadjah Mada
desmayantiastri@gmail.com

[Journal of Food and Pharmaceutical Sciences](#)

jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589#

English View Site ririnsuharsanti

Submission Library View Metadata

Notifications

[JFPS] Editor Decision

2025-06-02 06:57 PM

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita:

We have reached a decision regarding your submission to Journal of Food and Pharmaceutical Sciences, "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Our decision is to: Accept Submission

Astri Desmayanti
Universitas Gadjah Mada
desmayantiastri@gmail.com

[Journal of Food and Pharmaceutical Sciences](#)

Reviewer's Attachments

98490-1, 21589-Article Text-98044-1-4-20250517.docx May 21, 2025

Submission ID	Status	Date
2025-05-21 02:11 PM		2025-05-21 02:11 PM
2025-06-02 06:57 PM		2025-06-02 06:57 PM
2025-06-17 06:46 PM		2025-06-17 06:46 PM

6. Payment Request

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select Threads Options Refresh

Reply Reply all Forward Delete Archive Junk Mark More

Inbox Q JFPS

- Astri Desmayanti via Jurna... Today 12:46
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:47
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:46
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-06-12 11:42
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:58
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:57
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-05-21 14:11
- [JFPS] Editor Decision
- Prof. Dr. Abdul Rohm... 2025-05-16 12:11
- [JFPS] Submission Acknowledgement

[JFPS] New notification from Journal of Food and Pharmaceutical Sciences

From Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada on 2025-06-02 18:58

Details Headers Plain text

You have a new notification from Journal of Food and Pharmaceutical Sciences:

You have been added to a discussion titled "[JFPS] Publication Payment" regarding the submission "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Link: <https://jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589>

Prof. Dr. Abdul Rohman, M.Si., Apt

Journal of Food and Pharmaceutical Sciences

jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589#

English View Site

Submission Library View Me

[JFPS] Publication Payment

Participants

Astri Desmayanti (astridesmayanti92)

Ririn Suharsanti (ririnsuharsanti)

Messages

Note	From
Dear Author, Attached is the invoice for the publication of your article in the <i>Journal of Food and Pharmaceutical Sciences</i> . Kindly complete the payment and send the proof of transfer at your earliest convenience. Should you have any questions or require further assistance, please do not hesitate to contact us. Best regards, Editorial Team <i>Journal of Food and Pharmaceutical Sciences</i>	astridesmayanti92 2025-06-02 06:57 PM
Thank you for helping with the manuscript process up to the copyediting stage, we have sent proof of payment APC-21589 (attached)	ririnsuharsanti 2025-06-03 05:54 AM
Dear Author, Attached is the official payment receipt for your article publication in the <i>Journal of Food and Pharmaceutical Sciences</i> . This receipt serves as proof of your payment for the Article Processing Charge (APC) . Please keep this receipt for your records. If you require any further assistance or have any questions, feel free to contact us. Regards, Editor	astridesmayanti92 2025-06-12 11:42 AM

[astridesmayanti92, Invoice 21589.pdf](#)

[ririnsuharsanti, IMG-20250603-WA0000.jpg](#)

[astridesmayanti92, Receipt-Ririn Suharsanti.png](#)

7. Official payment receipt

Payment Receipt



Receipt Number : #015.21589
Payment Date : 03 June 2025
Payment Method : Bank Transfer

Received From:

Dr. apt. Ririn Suharsanti, M.Sc.
STIFAR Yayasan Pharmasi Semarang, Central Java, Indonesia
ririnsuharsanti@stifar.ac.id

Description	Quantity	Amount
Article Processing Charge - Journal of Food and Pharmaceutical Sciences - Vol.13 No.2 2025	1	Rp 800.000

Receiver,



Astri Desmayanti, S.Farm
(JFPS Managing Editor)

8. Proofreading of the Manuscript

Journal of Food and Pharmaceutical Sciences | Tasks 1 | English | View Site | ririnsuharsanti

Submission Library | View Metadata

In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, Lia Kusmita

Submission | Review | Copyediting | **Production**

Production Discussions

[Add discussion](#)

Name	From	Last Reply	Replies	Closed
[JFPS] Proofreading of the Manuscript	astridesmayanti92 2025-06-17 06:46 PM	ririnsuharsanti 2025-06-18 10:25 AM	1	<input type="checkbox"/>

Galleys

[PDF](#)

Platform & workflow by OJS / PKP

stifar.ac.id:2096/cpsess7079995234/3rdparty/roundcube/?_task=mail&_mbox=INBOX

ririnsuharsanti@stifar.ac.id

Select | Threads | Options | Refresh

Reply | Reply all | Forward | Delete | Archive | Junk | Mark | More

Compose | Mail | Contacts | Calendar | Settings | Webmail Home

Inbox | Drafts | Sent | Junk | Trash | Archive

Search: JFPS

- Astri Desmayanti via Jurna... Today 12:46
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:47
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-17 18:46
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-06-12 11:42
- [JFPS] New notification from Journa...
- Astri Desmayanti via ... 2025-06-02 18:58
- [JFPS] New notification from Journa...
- [JFPS] Editor Decision
- Astri Desmayanti via ... 2025-05-21 14:11
- [JFPS] Editor Decision
- Prof. Dr. Abdul Rohm... 2025-05-16 12:11
- [JFPS] Submission Acknowledgement

[JFPS] New notification from Journal of Food and Pharmaceutical Sciences

From Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada on 2025-06-17 18:47

[Details](#) | [Headers](#) | [Plain text](#)

You have a new notification from Journal of Food and Pharmaceutical Sciences:

You have been added to a discussion titled "[JFPS] Proofreading of the Manuscript" regarding the submission "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer".

Link: <https://jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589>

Prof. Dr. Abdul Rohman, M.Si., Apt

[Journal of Food and Pharmaceutical Sciences](#)

9. Editor decision-Send to Production

The screenshot shows an email client interface. The left sidebar contains navigation options: Compose, Mail, Contacts, Calendar, Settings, and Webmail Home. The main area displays an inbox with a search filter for 'JFPS'. The selected email is titled '[JFPS] New notification from Journal of Food and Pharmaceutical Sciences'. The email content includes a notification from Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada on 2025-06-17 18:47. The notification text states: 'You have a new notification from Journal of Food and Pharmaceutical Sciences: You have been added to a discussion titled "[JFPS] Proofreading of the Manuscript" regarding the submission "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer". Link: <https://jurnal.ugm.ac.id/v3/JFPS/authorDashboard/submission/21589> Prof. Dr. Abdul Rohman, M.Si., Apt'.

10. Revised copyediting of Manuscript

The screenshot shows the author dashboard for the submission 'In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer'. The dashboard includes sections for 'Participants' (Astri Desmayanti and Ririn Suharsanti), 'Messages', and 'Galley' (PDF). The 'Messages' section displays a message from Astri Desmayanti (astridesmayanti92) dated 2025-06-17 06:46 PM. The message content is: 'Dear Author, Here I attach the proofreading of the manuscript entitled "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer" Please check the galley proof carefully and give us the quote and revision, if any. We will publish this article on 30 June 2025 (Volume 13, Issue 2). Thank you, Editor JFPS'. A link to the proofreading file is provided: [astridesmayanti92, \[7\] PR_Ririn Suharsanti 92-99.pdf](#). A reply message from Ririn Suharsanti (ririnsuharsanti) dated 2025-06-18 10:25 AM is also shown: 'Thank you for the proofread file that has been provided. All parts of the article are correct except for the writing of the name "Curcuma aeruginosa" in the abstract which should be written in italics. We attach our correction file and have marked it with yellow highlights thank you Ririn Suharsanti'. A link to the correction file is provided: [ririnsuharsanti, confirm_21589-Article Text-101234-1-18-20250617.pdf](#).

11. Article Published Vol 13 issue 2 (30 Juni 2025) on Website

The screenshot shows an email client interface for the account `ririnsuharsanti@stifar.ac.id`. The inbox on the left lists several emails from Astri Desmayanti via Jurnal Ilmiah Universitas Gadjah Mada, including 'New notification from Journal of Food and Pharmaceutical Sciences', 'Editor Decision', and 'Submission Acknowledgement'. The main pane displays a notification from the journal, dated 2025-06-30 12:46, with a link to the current issue: <https://jurnal.ugm.ac.id/v3/JFPS/issue/current>. The notification is from Prof. Dr. Abdul Rohman, M.Si., Apt.

The screenshot shows the website for the Journal of Food and Pharmaceutical Sciences (jurnal.ugm.ac.id/v3/JFPS/article/view/21589). The page features the journal's logo and title, along with navigation links for Home, About, Editorial Team, Reviewer, Publication Ethics, Announcements, Current, Archives, and Archives Vol 1-6. The main article is titled "In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer" by Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, and Lia Kusmita. The authors' affiliations are listed as Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, Central Java, 50192, Indonesia. The article's DOI is <https://doi.org/10.22146/jfps.21589>. A thumbnail of the journal cover (Volume 13, No. 2, April-June 2025) is displayed. On the right side, there is a sidebar with a "New Submission" button and a "JOURNAL MENU" containing links for Focus & Scope, Open Access Policy, Copyright Notice, Sponsorship Disclosure, Journal History, Privacy Statement, Archival System, and Author Fees. An "Editorial Member" button is also visible at the bottom of the sidebar.

2 June 2025

Dear : Ririn Suharsanti


ACCEPTANCE LETTER

Journal of Food and Pharmaceutical Research (JFPS), is pleased to inform you that the following manuscript has been accepted for publication in JFPS volume 13 issue 2 on June 2025.

Manuscript Title : In Silico Study of Compounds Identified in *Curcuma aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer
Authors : Ririn Suharsanti, Muhammad Ryan Radix Rahardhian, and Lia Kusmita

We thank you for your fine contribution to the Journal of Food and Pharmaceutical Sciences and encourage you to submit other articles to the journal.

Your sincerely,



Prof. Dr. Abdul Rohman

Chief Editor

Journal of Food and Pharmaceutical Sciences



1 Original Article

2 **In Silico Study of Compounds Identified in *Curcuma***
3 ***aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors**
4 **in Melanoma Cancer**

5 Ririn Suharsanti^{*)}, Muhammad Ryan Radix Rahardhian, Lia Kusmita

6 Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang; Central Java, 50192, Indonesia

7 * Corresponding author: ririnsuharsanti@stifार.ac.id; Tel.: +6282136923586

8 Received: date; Accepted: date; Published: date

9

10 **Abstract:** *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in
11 various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and
12 anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast
13 and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb rhizome
14 in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract of *Curcuma*
15 *aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and ethanol (EF)
16 fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The docking
17 validation process was carried out on the native ligand N-(3-[[5-(4-chlorophenyl)-1H-pyrrolo [2,3b]pyridin3yl]
18 carbonyl]2,4-difluorophenyl) propane-1-sulfonamide. All compounds were prepared as ligands for molecular
19 docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native ligand showed RMSD
20 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
21 Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravni is still better as
22 K⁺ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as
23 vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural development
24 is needed for better activity.

25 **Keywords:** *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

26

27 **1. INTRODUCTION**

28 Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more
29 prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common
30 cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020,
31 melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an
32 estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting
33 chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients
34 have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive
35 in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine
36 (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the
37 potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in
38 silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF
39 inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which
40 provide an opportunity for other natural ingredients to have the same activity.

41 Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache,
42 obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content
43 has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as

44 curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%),
45 curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor
46 (29.39%) dan germacrone (21.21%) [8], monoterpen (21.47%) berupa β -pinen dan 1,8 cineol [9], 1,8-
47 cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18.1%) dan eucalyptol (17.9%) [11], β -pinene
48 (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were
49 successfully separated from the black turmeric extract using chromatography include germacrone,
50 zederone, dehydrocurdione, curcumenol, zedoarondiol dan isocurcumenol [13]; dehydrocurdione,
51 curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone,
52 Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon
53 and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various
54 activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and
55 anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to
56 breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been
57 no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer
58 in silico so that it is worthy of being processed.

59 2. MATERIALS AND METHODS

60 2.1. Chemical

61 Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All reagents
62 used for the research were of analytical grade.

63 2.2. Plant Collection

64 *C. aeruginosa* Roxb dried rhizome from the Center for Research and Development of Traditional
65 Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February 2000.

66 2.3. Instrumentation

67 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The
68 columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene
69 glycol), thickness 0.25 μ m, length: 30.0m, inside diameter: 0.25mm.

70 2.4. Software and Hardware

71 The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21]. The
72 natural chemical's 3D structure files were obtained from PubChem
73 (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking.
74 AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening,
75 and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop
76 running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64
77 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator
78 (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast
79 pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the
80 pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsms>) [22].

81 2.5. Extraction and Fractination

82 One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70% ethanol.
83 Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a revolving
84 vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar (n-
85 hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by
86 sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning
87 the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

88 2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

89 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The
90 columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene
91 glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm. The mobile phase used is helium
92 and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-MS conditions are ion-source
93 temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa; and 1 µl injector in split mode
94 with a split ratio of 153.0 with injection temperature of 300 °C. The temperature was raised to 320 °C
95 at the rate of 10 °C/min and held for 5 min. The total elution was 24 min.

96 2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

97 Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-1.5.6 was
98 used to carry out 3D interaction, docking, and binding investigations. The Protein Data Bank
99 provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery Studio
100 visualizer program is used to extract native ligands and water molecules from 3D structures to create
101 protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which was
102 retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after the
103 receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were
104 established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box
105 size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid
106 residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were
107 visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted
108 and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors
109 (HBD), the number of atom-to-atom bonds that can rotate (Torson), the logarithm of the coefficient
110 octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing
111 Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble
112 drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might
113 forecast the higher probability of success or failure because of drug penetration and absorption.
114 Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a
115 particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to
116 convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsn>) was used
117 to process the SMILES formatted compound in order to forecast chemical toxicity and
118 pharmacokinetics [22].

119 3. RESULTS AND DISCUSSION

120 3.1. Fraction Compounds

121 According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and diterpenes
122 (5.26%), with 31.58% of it being unknown. substances. The EF was made up of sesquiterpenes
123 (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes (42.86%), diterpenes
124 (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were present when IF was
125 identified. Curcumenol and epicurzerenone were the primary constituents of HF and EF, whereas
126 curcumenol and 2,4-Dispironorbornylcyclobuta-1,3-dione (ketene dimers) were the primary
127 constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown in Figure 1.

128

129

130

131

132

133


134

135

136

137

138




139

140

141

142




143

144

145

146




147

148

149

150

151




152

153


154

155



156

157



158


Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS

159

160 3.1. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

161 Redocking, or confirming the docking technique between the receptor and the native ligand, is the
 162 first step in molecular docking. RMSD 1.03A is the outcome of the validation procedure. Since the
 163 RMSD value is $\leq 2\text{\AA}$ the docking procedure can be deemed acceptable, and the RMSD obtained
 164 satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native
 165 ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E
 166 resistor is shown in figure 2. Vemuravenib, a commercial medication, was utilized as a control ligand
 167 against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (figure
 168 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.

169
170
171
172
173
174
175
176
177




178 **Figure 2.** 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before
179 and red = after redocking)

180 The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
181 Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnib is still
182 better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity between the receptor
183 and ligand was higher and the vice versa, the greater the binding affinity value, the affinity between
184 receptors and the ligands is getting lower [5], [22]. All three compounds do not bind to key amino
185 acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594 [22]. The
186 amino acid residues that were shown to interact with ligands displays in table 1 and illustrates the
187 interaction between ligands and the BRAF-V600E receptor using 2D visualization displays in figure
188 2.

189 **Table 1.** Molecular interactions present in the selected complex ligands and BRAF V600E receptor
190 and the amino acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/ Ki (μM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6,68	12,63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	-6,89	8,96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6,23	27,21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7,42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596

191
192



211 **Figure 3.** 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one
 212 (A), 4,4a,5,6,7,8-Hexahydro-1-phthalen-2(3H)-one (B), Cyclooctenone (C), and Vemurafenib (D)
 213 with BRAF V600E receptor

214 The likelihood that a molecule has the same or superior activity than BRAF V600E increases with the
 215 number of amino acid similarities between the reference chemical and crucial amino acid. GLN A:530,
 216 CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E receptor.
 217 The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549) as the
 218 reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better
 219 binding scores than vemurafenib and a decent MolDock score (≥ -158.139) and Rerank score ($\geq -$
 220 118.607) were recognized as possible hits [5].

221 Out of all the compounds, the three identified compounds found by GC-MS were found to have the
 222 smallest binding affinities. The pkCMS online tool was used to further investigate these compound's
 223 pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive diffusion to
 224 ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According to Lipinski's
 225 guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of less than 5.
 226 molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen bonds < 10 .
 227 Cell membranes are more readily penetrated by ligands with molecular weights less than 500 Da than
 228 by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil, and non-
 229 polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout the body
 230 and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of cell
 231 membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the target
 232 molecule decreases. Because they are more broadly distributed throughout the body and are kept in

lipid membranes for longer, excessively hydrophobic compounds typically have a high level of toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less. Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three compounds satisfied Lipinski's guidelines.

Table 2. Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco2 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance. AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a compound's predictive value is greater than 0.90, it is deemed to have high CaCO-2 permeability [26]. It has good permeability because the test results showed a value greater than 0.90. When the volume of distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<-0.15), it is deemed low; when it is greater than 2.81 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In table 3, all compounds are in the range volume distribution requirements so that it can be predicted that all these compounds can be distributed evenly to provide the same concentration as in blood plasma. Based on table 3, all ligands have good pharmacokinetic parameter.

Table 3. Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD _{ss} (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2-propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8-Hexahydrona	1.501	0.344	No	0.112	No	No

phthalen-2(3H)-one						
Cyclooctenone	1.487	0.136	No	0.213	No	No

259

260 4. CONCLUSION

261 The three best components of *C. aeruginosa* fraction with the smallest binding affinity and meet the
 262 pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
 263 Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravni is still
 264 better as K+ (-10.593,68kcal/mol). All three compounds do not bind to key amino acid residues of BRAF
 265 V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. All three compounds have good
 266 pharmacokinetic parameter. These results indicate that further structural development is needed for
 267 better activity.

268 **Acknowledgments:** We thank the Education Financial Services Center (Puslapdik) via the
 269 Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the
 270 financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi
 271 Dona for technical support for this research.

272 **Conflicts of interest:** The authors declare no conflict of interest

273 References

- 274 [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci.*
 275 *2021, Vol. 9, Page 63*, vol. 9, no. 4, p. 63, Oct. 2021.
- 276 [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*,
 277 vol. 8, no. 2, pp. 103–110, Aug. 2020.
- 278 [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant
 279 melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- 280 [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF
 281 V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- 282 [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-
 283 yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and
 284 drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- 285 [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia: attributed properties and uses.*
 286 Cambridge: MIT Press, 1980.
- 287 [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent.*
 288 *Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- 289 [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial
 290 activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma*
 291 *cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct.
 292 2017.
- 293 [9] J. Srivilai *et al.*, "*Curcuma aeruginosa* Roxb. essential oil slows hair-growth and lightens skin in axillae; a
 294 randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- 295 [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair
 296 Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no.
 297 2, pp. 99–106, Feb. 2018.
- 298 [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles
 299 and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*,"
 300 *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- 301 [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential
 302 oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–
 303 184, 2018.
- 304 [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-
 305 androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*,
 306 vol. 83, no. 5, pp. 864–871, 2012.
- 307 [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and

- 308 sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a
309 hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- 310 [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56,
311 no. 6, pp. 721–725, Dec. 2018.
- 312 [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from
313 *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J.*
314 *Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- 315 [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam
316 rhizome (*Curcuma aeruginosa* Roxb .)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- 317 [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*,
318 vol. 15, no. 1, pp. 1–7, Jun. 2015.
- 319 [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations:
320 cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13,
321 2024.
- 322 [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.),"
323 *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- 324 [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties,
325 Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopia vielana*
326 Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- 327 [22] Damayanti, C. Cita Rosita Sigit Prsakoewa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular
328 Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK
329 Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- 330 [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory
331 Activities , Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa*
332 Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- 333 [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of
334 *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- 335 [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster
336 drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- 337 [26] Herdini and I. R. Setyawati, "Studi In Silico : Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*)
338 terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*,
339 vol. 33, no. 2, pp. 81–97, 2023.
- 340 [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada *Pericarpium Pala*
341 (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.
- 342

In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

by Ririn Suharsanti

Submission date: 16-May-2025 11:58AM (UTC+0700)

Submission ID: 2673781456

File name: JFPS_Ririn_Suharsanti_16_Mei.pdf (1.5M)

Word count: 4448

Character count: 23441

1 Original Article

2 **In Silico Study of Compounds Identified in *Curcuma***
3 ***aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors**
4 **in Melanoma Cancer**

5 **Ririn Suharsanti^{*)}, Muhammad Ryan Radix Rahardhian, Lia Kusmita**

6 **Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, Central Java, 50192, Indonesia**

7 * Corresponding author: ririnsuharsanti@stifar.ac.id; Tel.: +6282136923586

8 Received: date; Accepted: date; Published: date

9

10 **Abstract:** *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in
11 various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and
12 anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast
13 and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb rhizome
14 in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract of *Curcuma*
15 *aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and ethanol (EF)
16 fractions. The GC-MS results showed that there were 51 compounds from the three fractions. The docking
17 validation process was carried out on the native ligand N-(3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3b]pyridin-3-yl]
18 carbonyl]2,4-difluorophenyl) propane-1-sulfonamide. All compounds were prepared as ligands for molecular
19 docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native ligand showed RMSD
20 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
21 Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravnb is still better as
22 K+ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as
23 vemuravnb at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural development
24 is needed for better activity.

25 **Keywords:** *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravnb

26

27 **1. INTRODUCTION**

28 Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more
29 prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common
30 cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020,
31 melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an
32 estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting
33 chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients
34 have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive
35 in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine
36 (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the
37 potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in
38 silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF
39 inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which
40 provide an opportunity for other natural ingredients to have the same activity.

41 Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache,
42 obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content
43 has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as

44 curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%),
45 curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor
46 (29.39%) dan germacrone (21.21%) [8], monoterpen (21.47%) berupa β -pinen dan 1,8 cineol [9], 1,8-
47 cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18.1%) dan eucalyptol (17.9%) [11], β -pinene
48 (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were
49 successfully separated from the black turmeric extract using chromatography include germacrone,
50 zederone, dehydrocurdione, curcumenol, γ -loarondiol dan isocurcumenol [13]; dehydrocurdione,
51 curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone,
52 Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon
53 and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various
54 activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and
55 anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to
56 breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been
57 no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer
58 in silico so that it is worthy of being processed.

59 2. MATERIALS AND METHODS

60 2.1. Chemical

61 Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All reagents
62 used for the research were of analytical grade.

63 2.2. Plant Collection

64 *C. aeruginosa* Roxb dried rhizome from the Center for Research and Development of Traditional
65 Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February 2000.

66 2.3. Instrumentation

67 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The
68 columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene
69 glycol), thickness 0.25 μ m, length: 30.0m, inside diameter: 0.25mm.

70 2.4. Software and Hardware

71 The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21]. The
72 natural chemical's 3D structure files were obtained from PubChem
73 (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking.
74 AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening,
75 and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop
76 running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64
77 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator
78 (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast
79 pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the
80 pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) [22].

81 2.5. Extraction and Fractination

82 One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70% ethanol.
83 Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a revolving
84 vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar (n-
85 hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by
86 sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning
87 the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

88 2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

89 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The
90 column used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene
91 glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm. The mobile phase used is helium
92 and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-MS conditions are ion-source
93 temperature, 250 °C; interface temperature, 300 °C; pressure, 42.5 kPa; and 1 µl injector in split mode
94 with a split ratio of 153.0 with injection temperature of 300 °C. The temperature was raised to 320 °C
95 at the rate of 10 °C/min and held for 5 min. The total elution was 24 min.

96 2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

97 Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-1.5.6 was
98 used to carry out 3D interaction, docking, and binding investigations. The Protein Data Bank
99 provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery Studio
100 visualizer program is used to extract native ligands and water molecules from 3D structures to create
101 protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which was
102 retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after the
103 receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were
104 established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box
105 size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid
106 residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were
107 visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted
108 and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors
109 (HBD), the number of atom-to-atom bonds that can rotate (Torsion), the logarithm of the coefficient
110 octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing
111 Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble
112 drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might
113 forecast the higher probability of success or failure because of drug penetration and absorption.
114 Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a
115 particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to
116 convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsms>) was used
117 to process the SMILES formatted compound in order to forecast chemical toxicity and
118 pharmacokinetics [22].

119 3. RESULTS AND DISCUSSION

120 3.1. Fraction Compounds

121 According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and diterpenes
122 (5.26%), with 31.58% of it being unknown substances. The EF was made up of sesquiterpenes
123 (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes (42.86%), diterpenes
124 (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were present when IF was
125 identified. Curcumenol and epicurzerenone were the primary constituents of HF and EF, whereas
126 curcumenol and 2,4-Dispironorbornylcyclobuta-1,3-dione (ketene dimers) were the primary
127 constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown in Figure 1.

128

129

130

131

132

133


134

135

136

137

138




139

140

141

142




143

144

145

146




147

148

149

150




151

152

153


154



155

156

157



158

Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS

159

160

3.1. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

161

162

163

164

165


166

167

168

Redocking, or confirming the docking technique between the receptor and the native ligand, is the first step in molecular docking. RMSD 1.03A is the outcome of the validation procedure. Since the RMSD value is $\leq 2A$ the docking procedure can be deemed acceptable, and the RMSD obtained satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E resistor is shown in figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (figure 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.

169
170
171
172
173
174
175
176
177




178 **Figure 2.** 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before
179 and red = after redocking)

180 The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
181 Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravni is still
182 better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity between the receptor
183 and ligand was higher and the vice versa, the greater the binding affinity value, the affinity between
184 receptors and the ligands is getting lower [5], [22]. All three compounds do not bind to key amino
185 acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594 [22]. The
186 amino acid residues that were shown to interact with ligands displays in table 1 and illustrates the
187 interaction between ligands and the BRAF-V600E receptor using 2D visualization displays in figure
188 2.

189 **Table 1.** Molecular interactions present in the selected complex ligands and BRAF V600E receptor
190 and the amino acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/ Ki (μ M)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6,68	12,63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	-6,89	8,96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6,23	27,21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7,42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530, Trp-531, Cys-532, Ser-535, Ser-536, His-539, Phe-583, Asp-594, Asp-593, Phe-595, Gly-596

191
192



211 **Figure 3.** 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one
 212 (A), 4,4a,5,6,7,8-Hexahydrophthalen-2(3H)-one (B), Cyclooctenone (C), and Vemurafenib (D)
 213 with BRAF V600E receptor

214 The likelihood that a molecule has the same or superior activity than BRAF V600E increases with the
 215 number of amino acid similarities between the reference chemical and crucial amino acid. GLN A:530,
 216 CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E receptor.
 217 The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549) as the
 218 reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better
 219 binding scores than vemurafenib and a decent MolDock score (≥ -158.139) and Rerank score (\geq
 220 -118.607) were recognized as possible hits [5].

221 Out of all the compounds, the three identified compounds found by GC-MS were found to have the
 222 smallest binding affinities. The pkCMS online tool was used to further investigate these compound's
 223 pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive diffusion to
 224 ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According to Lipinski's
 225 guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of less than 5.
 226 molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen bonds < 10 .
 227 Cell membranes are more readily penetrated by ligands with molecular weights less than 500 Da than
 228 by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil, and non-
 229 polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout the body
 230 and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of cell
 231 membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the target
 232 molecule decreases. Because they are more broadly distributed throughout the body and are kept in

lipid membranes for longer, excessively hydrophobic compounds typically have a high level of toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less. Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three compounds satisfied Lipinski's guidelines.

Table 2. Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

241

When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco2 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance. AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a compound's predictive value is greater than 0.90, it is deemed to have high CaCO-2 permeability [26]. It has good permeability because the test results showed a value greater than 0.90. When the volume of distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<0.15), it is deemed low; when it is greater than 2.81 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In table 3, all compounds are in the range volume distribution requirements so that it can be predicted that all these compounds can be distributed evenly to provide the same concentration as in blood plasma. Based on table 3, all ligands have good pharmacokinetic parameter.

258

Table 3. Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD _{ss} (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2-propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8-Hexahydrona	1.501	0.344	No	0.112	No	No

phthalen-2(3H)-one						
Cyclooctenone	1.487	0.136	No	0.213	No	No

259

260 4. CONCLUSION

261 The three best components of *C. aeruginosa* fraction with the smallest binding affinity and meet the
 262 pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-
 263 Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnb is still
 264 better as K⁺ (-10,593,68kcal/mol). All three compounds do not bind to key amino acid residues of BRAF
 265 V600E such as vemuravnb at GLN A:530, CYS A:532; ASP A:594. All three compounds have good
 266 pharmacokinetic parameter. These results indicate that further structural development is needed for
 267 better activity.

268 **Acknowledgments:** We thank the Education Financial Services Center (Puslapdik) via the
 269 Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the
 270 financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindia
 271 Dona for technical support for this research.

272 **Conflicts of interest:** The authors declare no conflict of interest

273 References

- 274 [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci.*
 275 2021, Vol. 9, Page 63, vol. 9, no. 4, p. 63, Oct. 2021.
- 276 [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*,
 277 vol. 8, no. 2, pp. 103–110, Aug. 2020.
- 278 [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant
 279 melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- 280 [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF
 281 V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- 282 [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-
 283 yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and
 284 drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- 285 [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia : attributed properties and uses.*
 286 Cambridge: MIT Press, 1980.
- 287 [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent.*
 288 *Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- 289 [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial
 290 activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma*
 291 *cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct.
 292 2017.
- 293 [9] J. Srivilai *et al.*, "*Curcuma aeruginosa* Roxb. essential oil slows hair-growth and lightens skin in axillae; a
 294 randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- 295 [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair
 296 Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no.
 297 2, pp. 99–106, Feb. 2018.
- 298 [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles
 299 and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*,"
 300 *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- 301 [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential
 302 oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–
 303 184, 2018.
- 304 [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-
 305 androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*,
 306 vol. 83, no. 5, pp. 864–871, 2012.
- 307 [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and

- 308 sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a
309 hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- 310 [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56,
311 no. 6, pp. 721–725, Dec. 2018.
- 312 [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from
313 *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J.*
314 *Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- 315 [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam
316 rhizome (*Curcuma aeruginosa* Roxb.)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- 317 [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*,
318 vol. 15, no. 1, pp. 1–7, Jun. 2015.
- 319 [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations:
320 cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13,
321 2024.
- 322 [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.),"
323 *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- 324 [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties,
325 Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopia vielana*
326 Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- 327 [22] Damayanti, C. Cita Rosita Sigit Prsakoewa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular
328 Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK
329 Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- 330 [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory
331 Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa*
332 Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- 333 [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of
334 *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- 335 [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster
336 drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- 337 [26] Herdini and I. R. Setyawati, "Studi In Silico : Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*)
338 terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*,
339 vol. 33, no. 2, pp. 81–97, 2023.
- 340 [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada Pericarpium Pala
341 (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.
- 342

In Silico Study of Compounds Identified in Curcuma aeruginosa Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

ORIGINALITY REPORT

18%

SIMILARITY INDEX

15%

INTERNET SOURCES

14%

PUBLICATIONS

6%

STUDENT PAPERS

PRIMARY SOURCES

1	tjnpr.org Internet Source	2%
2	fjps.springeropen.com Internet Source	2%
3	Submitted to Universitas Jenderal Achmad Yani Student Paper	2%
4	journal.uinsgd.ac.id Internet Source	2%
5	Submitted to Konsorsium Perguruan Tinggi Swasta Indonesia Student Paper	1%
6	dev.journal.ugm.ac.id Internet Source	1%
7	www.freepatentsonline.com Internet Source	1%
8	ejournal3.undip.ac.id Internet Source	1%
9	updatepublishing.com Internet Source	1%
10	www.scilit.net Internet Source	1%
11	rjmp.scione.com Internet Source	1%

12 Asmi Citra Malina A.R Tasakka, Israini Wiyulanda Iskandar, Sulfahri, Eko Agus Suyono et al. "Molecular docking analysis of selected natural products from Halymenia sp. and Laurencia sp. seaweeds against plasmepsins as antimalarials", IOP Conference Series: Earth and Environmental Science, 2022
Publication 1%

13 Abdullahi Bello Umar, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba. "Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors", Egyptian Journal of Medical Human Genetics, 2020
Publication 1%

14 Hasnah M. Sirat, Shajarahtunnur Jamil, Jauhari Hussain. " Essential Oil of Roxb. from Malaysia ", Journal of Essential Oil Research, 1998
Publication 1%

15 Submitted to iGroup
Student Paper 1%

16 tesis.ucsm.edu.pe
Internet Source 1%

Exclude quotes On

Exclude matches < 1%

Exclude bibliography On

In Silico Study of Compounds Identified in *Curcuma aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Received: date; Accepted: date; Published: date

Abstract: *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb rhizome in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract of *Curcuma aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and ethanol (EF) fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The docking validation process was carried out on the native ligand N-(3-([5-(4-chlorophenyl)-1H-pyrrolo [2,3b]pyridin-3-yl]carbonyl)2,4-difluorophenyl) propane-1-sulfonamide. All compounds were prepared as ligands for molecular docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native ligand showed RMSD 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravnb is still better as K⁺ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural development is needed for better activity.

Keywords: *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

1. INTRODUCTION

Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020, melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which provide an opportunity for other natural ingredients to have the same activity.

Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache, obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%), curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor (29,39%) dan germacrone (21,21%) [8], monoterpen (21,47%) berupa β -pinen dan 1,8 cineol [9], 1,8-

cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18,1%) dan eucalyptol (17,9%) [11], β -pinene (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were successfully separated from the black turmeric extract using chromatography include germacrone, zederone, dehydrocurdione, curcumenol, zedoaronidiol dan isocurcumenol [13]; dehydrocurdione, curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone, Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer in silico so that it is worthy of being processed.

2. MATERIALS AND METHODS

2.1. Chemical

Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All reagents used for the research were of analytical grade.

2.2. Plant Collection

C. aeruginosa Roxb dried rhizome from the Center for Research and Development of Traditional Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February 2000.

2.3. Instrumentation

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene glycol), thickness 0.25 μ m, length: 30.0m, inside diameter: 0.25mm.

2.4. Software and Hardware

The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21]. The natural chemical's 3D structure files were obtained from PubChem (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking. AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening, and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) [22].

2.5. Extraction and Fractination

One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70% ethanol. Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a revolving vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar (n-hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene

Commented [AS1]: is it true that the sample was harvested in 2000?

glycol), thickness 0.25µm, length: 30.0m, inside diameter: 0.25mm. The mobile phase used is helium and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-MS conditions are ion-source temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa; and 1 µl injector in split mode with a split ratio of 153.0 with injection temperature of 300 °C. The temperature was raised to 320 °C at the rate of 10 °C/min and held for 5 min. The total elution was 24 min.

2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-1.5.6 was used to carry out 3D interaction, docking, and binding investigations. The Protein Data Bank provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery Studio visualizer program is used to extract native ligands and water molecules from 3D structures to create protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which was retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after the receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), the number of atom-to-atom bonds that can rotate (Torsion), the logarithm of the coefficient octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might forecast the higher probability of success or failure because of drug penetration and absorption. Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) was used to process the SMILES formatted compound in order to forecast chemical toxicity and pharmacokinetics [22].

3. RESULTS AND DISCUSSION

3.1. Fraction Compounds

According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and diterpenes (5.26%), with 31.58% of it being unknown substances. The EF was made up of sesquiterpenes (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes (42.86%), diterpenes (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were present when IF was identified. Curcumenol and epicurzerenone were the primary constituents of HF and EF, whereas curcumenol and 2,4-Dispironbornylcyclobuta-1,3-dione (ketene dimers) were the primary constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown in Figure 1.

Commented [AS2]: the picture is tidied up even more




Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS

3.1. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Redocking, or confirming the docking technique between the receptor and the native ligand, is the first step in molecular docking. RMSD 1.03Å is the outcome of the validation procedure. Since the RMSD value is $\leq 2\text{Å}$ the docking procedure can be deemed acceptable, and the RMSD obtained satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E resistor is shown in Figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (Figure 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.




Figure 2. 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before and red = after redocking)

The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnib is still better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity between the receptor and ligand was higher and the vice versa, the greater the binding affinity value, the affinity between receptors and the ligands is getting lower [5], [22]. All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594 [22]. The amino acid residues that were shown to interact with ligands displays in Table 1 and illustrates the interaction between ligands and the BRAF-V600E receptor using 2D visualization displays in Figure 2.

Table 1. Molecular interactions present in the selected complex ligands and BRAF V600E receptor and the amino acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/ Ki (µM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6,68	12,63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	-6,89	8,96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6,23	27,21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7,42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596




Figure 3. 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one (A), 4,4a,5,6,7,8-Hexahydro-2(3H)-phthalen-1-one (B), Cyclooctenone (C), and Vemurafenib (D) with BRAF V600E receptor

Commented [AS3]: the picture is tidied up even more

The likelihood that a molecule has the same or superior activity than BRAF V600E increases with the number of amino acid similarities between the reference chemical and crucial amino acid. GLN A:530, CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E receptor. The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549) as the reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better binding scores than vemurafenib and a decent MolDock score (≥ 158.139) and Rerank score (≥ 118.607) were recognized as possible hits [5].

Out of all the compounds, the three identified compounds found by GC-MS were found to have the smallest binding affinities. The pkCMS online tool was used to further investigate these compound's pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive diffusion to ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According to Lipinski's guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of less than 5, molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen bonds < 10 . Cell membranes are more readily penetrated by ligands with molecular weights less than 500 Da than by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil, and non-polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout the body and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of cell membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the target molecule decreases. Because they are more broadly distributed throughout the body and are kept in

lipid membranes for longer, excessively hydrophobic compounds typically have a high level of toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less. Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three compounds satisfied Lipinski's guidelines.

Table 2. Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco2 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance. AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a compound's predictive value is greater than 0.90, it is deemed to have high CaCO-2 permeability [26]. It has good permeability because the test results showed a value greater than 0.90. When the volume of distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<0.15), it is deemed low; when it is greater than 2.81 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In Table 3, all compounds are in the range volume distribution requirements so that it can be predicted that all these compounds can be distributed evenly to provide the same concentration as in blood plasma. Based on Table 3, all ligands have good pharmacokinetic parameter.

Commented [A54]: Check again how to write CaCo2 correctly

Table 3. Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD _{ss} (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2-propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	1.501	0.344	No	0.112	No	No

phthalen-2(3H)-one						
Cyclooctenone	1.487	0.136	No	0.213	No	No

4. CONCLUSION

Commented [A55]: Adjust to the research objectives

The three best components of *C. aeruginosa* fraction with the smallest binding affinity and meet the pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnb is still better as K+ (-10.593,68kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. All three compounds have good pharmacokinetic parameter. These results indicate that further structural development is needed for better activity.

Acknowledgments: We thank the Education Financial Services Center (Puslapdik) via the Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi Dona for technical support for this research.

Conflicts of interest: The authors declare no conflict of interest

References

- [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci. 2021, Vol. 9, Page 63*, vol. 9, no. 4, p. 63, Oct. 2021.
- [2] M. A. Syakir and D. I. Angraini, "Terapi Imunologi Pada Melanoma," *JIMKIJ. Ilm. Mhs. Kedokt. Indones.*, vol. 8, no. 2, pp. 103–110, Aug. 2020.
- [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia: attributed properties and uses*. Cambridge: MIT Press, 1980.
- [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent. Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct. 2017.
- [9] J. Srivilai *et al.*, "*Curcuma aeruginosa* Roxb. essential oil slows hair-growth and lightens skin in axillae; a randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no. 2, pp. 99–106, Feb. 2018.
- [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*," *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–184, 2018.
- [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*, vol. 83, no. 5, pp. 864–871, 2012.
- [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and

- sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56, no. 6, pp. 721–725, Dec. 2018.
- [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J. Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam rhizome (*Curcuma aeruginosa* Roxb.)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*, vol. 15, no. 1, pp. 1–7, Jun. 2015.
- [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations: cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13, 2024.
- [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.)," *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopia vielana* Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- [22] Damayanti, C. Cita Rosita Sigit Prsakoewa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa* Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodijati*, vol. 9, no. November, pp. 228–243, 2024.
- [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- [26] Herdini and I. R. Setyawati, "Studi In Silico: Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*) terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*, vol. 33, no. 2, pp. 81–97, 2023.
- [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada *Pericarpium Pala* (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.

In Silico Study of Compounds Identified in *Curcuma aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Received: date; Accepted: date; Published: date

Abstract: *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb rhizome in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract of *Curcuma aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and ethanol (EF) fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The docking validation process was carried out on the native ligand N-(3-[[5-(4-chlorophenyl)-1H-pyrrolo [2,3b]pyridin-3-yl] carbonyl]2,4-difluorophenyl) propane-1-sulfonamide. All compounds were prepared as ligands for molecular docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native ligand showed RMSD 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravni is still better as K⁺ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural development is needed for better activity.

Keywords: *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

1. INTRODUCTION

Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020, melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which provide an opportunity for other natural ingredients to have the same activity.

Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache, obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%), curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor (29,39%) dan germacrone (21,21%) [8], monoterpen (21,47%) berupa β -pinen dan 1,8 cineol [9], 1,8-

cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18,1%) dan eucalyptol (17,9%) [11], β -pinene (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were successfully separated from the black turmeric extract using chromatography include germacrone, zederone, dehydrocurdione, curcumenol, zedoarondiol dan isocurcumenol [13]; dehydrocurdione, curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone, Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer in silico so that it is worthy of being processed.

2. MATERIALS AND METHODS

2.1. Chemical

Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All reagents used for the research were of analytical grade.

2.2. Plant Collection

C. aeruginosa Roxb dried rhizome from the Center for Research and Development of Traditional Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February 2020.

2.3. Instrumentation

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene glycol), thickness 0.25 μ m, length: 30.0m, inside diameter: 0.25mm.

2.4. Software and Hardware

The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21]. The natural chemical's 3D structure files were obtained from PubChem (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking. AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening, and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) [22].

2.5. Extraction and Fractination

One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70% ethanol. Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a revolving vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar (n-hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene

glycol), thickness 0.25µm, length: 30.0m, inside diameter: 0.25mm. The mobile phase used is helium and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-MS conditions are ion-source temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa; and 1 µl injector in split mode with a split ratio of 153.0 with injection temperature of 300 °C. The temperature was raised to 320 °C at the rate of 10 °C/min and held for 5 min. The total elution was 24 min.

2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-1.5.6 was used to carry out 3D interaction, docking, and binding investigations. The Protein Data Bank provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery Studio visualizer program is used to extract native ligands and water molecules from 3D structures to create protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which was retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after the receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), the number of atom-to-atom bonds that can rotate (Torson), the logarithm of the coefficient octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might forecast the higher probability of success or failure because of drug penetration and absorption. Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsml>) was used to process the SMILES formatted compound in order to forecast chemical toxicity and pharmacokinetics [22].

3. RESULTS AND DISCUSSION

3.1. Fraction Compounds

According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and diterpenes (5.26%), with 31.58% of it being unknown substances. The EF was made up of sesquiterpenes (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes (42.86%), diterpenes (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were present when IF was identified. Curcumenol and epicurzerenone were the primary constituents of HF and EF, whereas curcumenol and 2,4-Dispironorbonylcyclobuta-1,3-dione (ketene dimers) were the primary constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown in Figure 1.




Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS

3.1. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Redocking, or confirming the docking technique between the receptor and the native ligand, is the first step in molecular docking. RMSD 1.03A is the outcome of the validation procedure. Since the RMSD value is $\leq 2\text{\AA}$ the docking procedure can be deemed acceptable, and the RMSD obtained satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E receptor is shown in Figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (Figure 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.




Figure 2. 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before and red = after redocking)

The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnib is still better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity between the receptor and ligand was higher and the vice versa, the greater the binding affinity value, the affinity between receptors and the ligands is getting lower [5], [22]. All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594 [22]. The amino acid residues that were shown to interact with ligands displays in Table 1 and illustrates the interaction between ligands and the BRAF-V600E receptor using 2D visualization displays in Figure 2.

Table 1. Molecular interactions present in the selected complex ligands and BRAF V600E receptor and the amino acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/ Ki (µM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6,68	12,63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phtalen-2(3H)-one	-6,89	8,96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6,23	27,21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7,42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596




Figure 3. 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one (A), 4,4a,5,6,7,8-Hexahydro-na phthalen-2(3H)-one (B), Cyclooctenone (C), and Vemuravenib (D) with BRAF V600E receptor

The likelihood that a molecule has the same or superior activity than BRAF V600E increases with the number of amino acid similarities between the reference chemical and crucial amino acid. GLN A:530, CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E receptor. The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549) as the reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better binding scores than vemurafenib and a decent MolDock score (≥ -158.139) and Rerank score (≥ -118.607) were recognized as possible hits [5].

Out of all the compounds, the three identified compounds found by GC-MS were found to have the smallest binding affinities. The pkCMS online tool was used to further investigate these compound's pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive diffusion to ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According to Lipinski's guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of less than 5. molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen bonds < 10 . Cell membranes are more readily penetrated by ligands with molecular weights less than 500 Da than by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil, and non-polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout the body and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of cell

membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the target molecule decreases. Because they are more broadly distributed throughout the body and are kept in lipid membranes for longer, excessively hydrophobic compounds typically have a high level of toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less. Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three compounds satisfied Lipinski's guidelines.

Table 2. Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco-2 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance. AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a compound's predictive value is greater than 0.90, it is deemed to have high Caco-2 permeability [26]. It has good permeability because the test results showed a value greater than 0.90. When the volume of distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<0.15), it is deemed low; when it is greater than 2.81 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In Table 3, all compounds are in the range volume distribution requirements so that it can be predicted that all these compounds can be distributed evenly to provide the same concentration as in blood plasma. Based on Table 3, all ligands have good pharmacokinetic parameter.

Table 3. Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VDss (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2-propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	1.501	0.344	No	0.112	No	No
Cyclooctenone	1.487	0.136	No	0.213	No	No

4. CONCLUSION

The best potential components exploration of *C. aeruginosa* fraction with the smallest binding affinity and meet the pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravni is still better as K+ (-10.593,68kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravni at GLN A:530, CYS A:532; ASP A:594. All three compounds have good pharmacokinetic parameter. These results indicate that further structural development is needed for better activity.

Acknowledgments: We thank the Education Financial Services Center (Puslapdik) via the Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi Dona for technical support for this research.

Conflicts of interest: The authors declare no conflict of interest

References

- [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci. 2021, Vol. 9, Page 63*, vol. 9, no. 4, p. 63, Oct. 2021.
- [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*, vol. 8, no. 2, pp. 103–110, Aug. 2020.
- [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia: attributed properties and uses*. Cambridge: MIT Press, 1980.
- [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent. Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct. 2017.
- [9] J. Srivilai *et al.*, "*Curcuma aeruginosa* Roxb. essential oil slows hair-growth and lightens skin in axillae; a randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no. 2, pp. 99–106, Feb. 2018.

- [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*," *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–184, 2018.
- [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*, vol. 83, no. 5, pp. 864–871, 2012.
- [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56, no. 6, pp. 721–725, Dec. 2018.
- [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J. Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam rhizome (*Curcuma aeruginosa* Roxb .)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*, vol. 15, no. 1, pp. 1–7, Jun. 2015.
- [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations: cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13, 2024.
- [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.)," *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopia vielana* Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- [22] Damayanti, C. Cita Rosita Sigit Prsakoeswa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory Activities , Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa* Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- [26] Herdini and I. R. Setyawati, "Studi In Silico : Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*) terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*, vol. 33, no. 2, pp. 81–97, 2023.
- [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada *Pericarpium Pala* (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.

INVOICE

Invoice Number : 015-JFPS-2025-INV-21589
Billing Date : June 2, 2025
Payment Due Date : June 16, 2025

Bill To:

Ririn Suharsanti

STIFAR Yayasan Pharmasi, Semarang, Central Java, Indonesia

ririnsuharsanti@stifar.ac.id

Description of Services

No.	Description	Quantity	Unit Price (Rp)	Total (Rp)
1.	Article Processing Charge	1	800.000	800.000
			Total Amount Due	800.000

Payment Instructions:

Bank Name: BNI (Bank Negara Indonesia)

Name: Astri Desmayanti

Account Number: 1115216016

Payment Details: APC-21589 **(Please write in the transfer details)**

Please ensure the payment is made before the deadline and send the proof of payment to journal system or email jfoodpharmsci.gama@gmail.com for confirmation.

Thank you for your contribution!

Best Regards

Editorial Team

Journal of Food and Pharmaceutical Sciences



1 Original Article

2 **In Silico Study of Compounds Identified in *Curcuma***
3 ***aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in**
4 **Melanoma Cancer**

5 Ririn Suharsanti*), Muhammad Ryan Radix Rahardhian, Lia Kusmita

6 Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang; Central Java, 50192, Indonesia

7 *Corresponding author: Ririn Suharsanti | Email: ririnsuharsanti@stifar.ac.id

8 Received: 16 May 2025; Revised: 22 May 2025; Accepted: 02 June 2025; Published: June 2025

9 **Abstract:** *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in
10 various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and
11 anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast
12 and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb
13 rhizome in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract
14 of *Curcuma aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and
15 ethanol (EF) fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The
16 docking validation process was carried out on the native ligand N-(3-([5-(4-chlorophenyl)-1H-pyrrolo
17 [2,3b]pyridin-3-yl)carbonyl]2,4-difluorophenyl)propane-1-sulfonamide. All compounds were prepared as
18 ligands for molecular docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native
19 ligand showed RMSD 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-
20 6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravni
21 b is still better as K+ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF
22 V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural
23 development is needed for better activity.

24 **Keywords:** *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

26 **1. INTRODUCTION**

27 Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more
28 prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common
29 cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020,
30 melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an
31 estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting
32 chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients
33 have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive
34 in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine
35 (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the
36 potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in
37 silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF
38 inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which
39 provide an opportunity for other natural ingredients to have the same activity.

40 Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache,
41 obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content
42 has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as
43 curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%),
44 curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor
45 (29,39%) dan germacrone (21,21%) [8], monoterpen (21,47%) berupa β -pinen dan 1,8 cineol [9], 1,8-

46 cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18,1%) dan eucalyptol (17,9%) [11], β -pinene
47 (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were
48 successfully separated from the black turmeric extract using chromatography include germacrone,
49 zederone, dehydrocurdione, curcumenol, zedoarondiol dan isocurcumenol [13]; dehydrocurdione,
50 curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone,
51 Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon
52 and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various
53 activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and
54 anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to
55 breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been
56 no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer
57 in silico so that it is worthy of being processed.

58 2. MATERIALS AND METHODS

59 2.1. Chemical

60 Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All
61 reagents used for the research were of analytical grade.

62 2.2. Plant Collection

63 *C. aeruginosa* Roxb dried rhizome from the Center for Research and Development of
64 Traditional Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February
65 2020.

66 2.3. Instrumentation

67 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass
68 spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and
69 Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm.

70 2.4. Software and Hardware

71 The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21].
72 The natural chemical's 3D structure files were obtained from PubChem
73 (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking.
74 AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening,
75 and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop
76 running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64
77 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator
78 (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast
79 pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the
80 pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsms>) [22].

81 2.5. Extraction and Fractination

82 One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70%
83 ethanol. Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a
84 revolving vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar
85 (n-hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by
86 sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning
87 the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

88 2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

89 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass
90 spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and
91 Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm. The
92 mobile phase used is helium and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-

93 MS conditions are ion-source temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa;
94 and 1 µl injector in split mode with a split ratio of 153.0 with injection temperature of 300 °C. The
95 temperature was raised to 320 °C at the rate of 10 °C/min and held for 5 min. The total elution was 24
96 min.

97 2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

98 Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-
99 1.5.6 was used to carry out 3D interaction, docking, and binding investigations. The Protein Data
100 Bank provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery
101 Studio visualizer program is used to extract native ligands and water molecules from 3D structures
102 to create protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which
103 was retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after
104 the receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were
105 established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box
106 size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid
107 residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were
108 visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted
109 and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors
110 (HBD), the number of atom-to-atom bonds that can rotate (Torson), the logarithm of the coefficient
111 octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing
112 Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble
113 drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might
114 forecast the higher probability of success or failure because of drug penetration and absorption.
115 Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a
116 particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to
117 convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) was used
118 to process the SMILES formatted compound in order to forecast chemical toxicity and
119 pharmacokinetics [22].

120 3. RESULTS AND DISCUSSION

121 3.1. Fraction Compounds

122 According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and
123 diterpenes (5.26%), with 31.58% of it being unknown substances. The EF was made up of
124 sesquiterpenes (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes
125 (42.86%), diterpenes (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were
126 present when IF was identified. Curcumenol and epicurzerenone were the primary constituents of
127 HF and EF, whereas curcumenol and 2,4-Dispironorbonylcyclobuta-1,3-dione (ketene dimers) were
128 the primary constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown
129 in Figure 1.

130 3.2. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

131 Redocking, or confirming the docking technique between the receptor and the native ligand, is
132 the first step in molecular docking. RMSD 1.03Å is the outcome of the validation procedure. Since the
133 RMSD value is ≤ 2Å the docking procedure can be deemed acceptable, and the RMSD obtained
134 satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native
135 ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E
136 resistor is shown in Figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand
137 against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (Figure
138 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.




Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS





Figure 2. 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before and red = after redocking)

151 The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89
 152 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and
 153 vemuravnib is still better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity
 154 between the receptor and ligand was higher and the vice versa, the greater the binding affinity value,
 155 the affinity between receptors and the ligands is getting lower [5], [22]. All three compounds do not
 156 bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP
 157 A:594 [22]. The amino acid residues that were shown to interact with ligands displays in Table 1 and
 158 illustrates the interaction between ligands and the BRAF-V600E receptor using 2D visualization
 159 displays in Figure 2.

160 **Table 1.** Molecular interactions present in the selected complex ligands and BRAF V600E receptor and the amino
 161 acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/Ki (µM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6.68	12.63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	-6.89	8.96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6.23	27.21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7.42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596



176
 177 **Figure 3.** 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one
 178 (A), 4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one (B), Cyclooctenone (C), and Vemuravenib (D)
 179 with BRAF V600E receptor

180 The likelihood that a molecule has the same or superior activity than BRAF V600E increases
 181 with the number of amino acid similarities between the reference chemical and crucial amino acid. GLN
 182 A:530, CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E
 183 receptor. The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549)
 184 as the reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better
 185 binding scores than vemurafe-nib and a decent MolDock score (≥ -158.139) and Rerank score ($\geq -$
 186 118.607) were recognized as possible hits [5].

187 Out of all the compounds, the three identified compounds found by GC-MS were found to
 188 have the smallest binding affinities. The pkCMS online tool was used to further investigate these
 189 compound's pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive
 190 diffusion to ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According
 191 to Lipinski's guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of
 192 less than 5. molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen
 193 bonds < 10 . Cell membranes are more readily penetrated by ligands with molecular weights less than
 194 500 Da than by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil,
 195 and non-polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout
 196 the body and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of
 197 cell membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the
 198 target molecule decreases. Because they are more broadly distributed throughout the body and are kept
 199 in lipid membranes for longer, excessively hydrophobic compounds typically have a high level of
 200 toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less.
 201 Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The
 202 biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor
 203 and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen
 204 bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three
 205 compounds satisfied Lipinski's guidelines.

206 **Table 2.** Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

207
 208 When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET
 209 estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco-2
 210 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug
 211 absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human
 212 intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same
 213 concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion
 214 in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and
 215 biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance.
 216 AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using
 217 bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a
 218 compound's predictive value is greater than 0.90, it is deemed to have high Caco-2 permeability [26]. It

219 has good permeability because the test results showed a value greater than 0.90. When the volume of
 220 distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<-0.15), it is deemed low; when it is greater than 2.81
 221 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In Table 3, all compounds are in the range volume
 222 distribution requirements so that it can be predicted that all these compounds can be distributed evenly
 223 to provide the same concentration as in blood plasma. Based on Table 3, all ligands have good
 224 pharmacokinetic parameter.

225 **Table 3.** Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD ss (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2- propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8- Hexahydrona phthalen-2(3H)-one	1.501	0.344	No	0.112	No	No
Cyclooctenone	1.487	0.136	No	0.213	No	No

226

227 4. CONCLUSION

228 The best potential components exploration of *C. aeruginosa* fraction with the smallest binding
 229 affinity and meet the pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-
 230 one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol);
 231 and vemuravnib is still better as K+ (-10.593,68kcal/mol). All three compounds do not bind to key
 232 amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. All
 233 three compounds have good pharmacokinetic parameter. These results indicate that further
 234 structural development is needed for better activity.

235 **Acknowledgments:** We thank the Education Financial Services Center (Puslapdik) via the
 236 Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the
 237 financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi
 238 Dona for technical support for this research.

239 **Conflicts of interest:** The authors declare no conflict of interest

240 References

- 241 [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci.*
 242 *2021, Vol. 9, Page 63*, vol. 9, no. 4, p. 63, Oct. 2021.
- 243 [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*,
 244 vol. 8, no. 2, pp. 103–110, Aug. 2020.
- 245 [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant
 246 melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- 247 [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF
 248 V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- 249 [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-
 250 yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and
 251 drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- 252 [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia : attributed properties and uses.*
 253 Cambridge: MIT Press, 1980.
- 254 [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent.*
 255 *Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- 256 [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial
 257 activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma*

- 258 *cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct.
259 2017.
- 260 [9] J. Srivilai *et al.*, "Curcuma aeruginosa Roxb. essential oil slows hair-growth and lightens skin in axillae; a
261 randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- 262 [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair
263 Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no.
264 2, pp. 99–106, Feb. 2018.
- 265 [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles
266 and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*,"
267 *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- 268 [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential
269 oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–
270 184, 2018.
- 271 [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-
272 androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*,
273 vol. 83, no. 5, pp. 864–871, 2012.
- 274 [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and
275 sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a
276 hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- 277 [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56,
278 no. 6, pp. 721–725, Dec. 2018.
- 279 [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from
280 *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J.*
281 *Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- 282 [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam
283 rhizome (*Curcuma aeruginosa* Roxb.)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- 284 [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*,
285 vol. 15, no. 1, pp. 1–7, Jun. 2015.
- 286 [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations:
287 cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13,
288 2024.
- 289 [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.),"
290 *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- 291 [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties,
292 Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopiella vielana*
293 Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- 294 [22] Damayanti, C. Cita Rosita Sigit Prsakoeswa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular
295 Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK
296 Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- 297 [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory
298 Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa*
299 Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- 300 [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of
301 *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- 302 [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster
303 drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- 304 [26] Herdini and I. R. Setyawati, "Studi In Silico: Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*)
305 terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*,
306 vol. 33, no. 2, pp. 81–97, 2023.
- 307 [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada Pericarpium Pala
308 (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.



© 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

1 Original Article

2 **In Silico Study of Compounds Identified in *Curcuma***
3 ***aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in**
4 **Melanoma Cancer**

5 Ririn Suharsanti*), Muhammad Ryan Radix Rahardhian, Lia Kusmita

6 Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang; Central Java, 50192, Indonesia

7 *Corresponding author: Ririn Suharsanti | Email: ririnsuharsanti@stifar.ac.id

8 Received: 16 May 2025; Revised: 22 May 2025; Accepted: 02 June 2025; Published: June 2025

9 **Abstract:** *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in
10 various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and
11 anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast
12 and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb
13 rhizome in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract
14 of *Curcuma aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and
15 ethanol (EF) fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The
16 docking validation process was carried out on the native ligand N-(3-([5-(4-chlorophenyl)-1H-pyrrolo
17 [2,3b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl)propane-1-sulfonamide. All compounds were prepared as
18 ligands for molecular docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native
19 ligand showed RMSD 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-
20 6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravni
21 b is still better as K⁺ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF
22 V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural
23 development is needed for better activity.

24 **Keywords:** *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

26 **1. INTRODUCTION**

27 Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more
28 prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common
29 cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020,
30 melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an
31 estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting
32 chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients
33 have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive
34 in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine
35 (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the
36 potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in
37 silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF
38 inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which
39 provide an opportunity for other natural ingredients to have the same activity.

40 Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache,
41 obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content
42 has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as
43 curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%),
44 curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor
45 (29,39%) dan germacrone (21,21%) [8], monoterpen (21,47%) berupa β-pinen dan 1,8 cineol [9], 1,8-

46 cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18,1%) dan eucalyptol (17,9%) [11], β -pinene
47 (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were
48 successfully separated from the black turmeric extract using chromatography include germacrone,
49 zederone, dehydrocurdione, curcumenol, zedoarondiol dan isocurcumenol [13]; dehydrocurdione,
50 curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone,
51 Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon
52 and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various
53 activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and
54 anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to
55 breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been
56 no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer
57 in silico so that it is worthy of being processed.

58 2. MATERIALS AND METHODS

59 2.1. Chemical

60 Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All
61 reagents used for the research were of analytical grade.

62 2.2. Plant Collection

63 *C. aeruginosa* Roxb dried rhizome from the Center for Research and Development of
64 Traditional Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February
65 2020.

66 2.3. Instrumentation

67 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass
68 spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and
69 Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm.

70 2.4. Software and Hardware

71 The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21].
72 The natural chemical's 3D structure files were obtained from PubChem
73 (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking.
74 AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening,
75 and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop
76 running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64
77 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator
78 (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast
79 pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the
80 pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsms>) [22].

81 2.5. Extraction and Fractination

82 One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70%
83 ethanol. Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a
84 revolving vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar
85 (n-hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by
86 sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning
87 the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

88 2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

89 GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass
90 spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and
91 Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm. The
92 mobile phase used is helium and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-

93 MS conditions are ion-source temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa;
94 and 1 µl injector in split mode with a split ratio of 153.0 with injection temperature of 300 °C. The
95 temperature was raised to 320 °C at the rate of 10 °C/min and held for 5 min. The total elution was 24
96 min.

97 2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

98 Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-
99 1.5.6 was used to carry out 3D interaction, docking, and binding investigations. The Protein Data
100 Bank provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery
101 Studio visualizer program is used to extract native ligands and water molecules from 3D structures
102 to create protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which
103 was retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after
104 the receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were
105 established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box
106 size is 44 × 40 × 40Å, spacing 0.375. Molecular docking parameters include interacting amino acid
107 residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were
108 visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted
109 and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors
110 (HBD), the number of atom-to-atom bonds that can rotate (Torson), the logarithm of the coefficient
111 octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing
112 Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble
113 drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might
114 forecast the higher probability of success or failure because of drug penetration and absorption.
115 Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a
116 particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to
117 convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcsml>) was used
118 to process the SMILES formatted compound in order to forecast chemical toxicity and
119 pharmacokinetics [22].

120 3. RESULTS AND DISCUSSION

121 3.1. Fraction Compounds

122 According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and
123 diterpenes (5.26%), with 31.58% of it being unknown substances. The EF was made up of
124 sesquiterpenes (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes
125 (42.86%), diterpenes (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were
126 present when IF was identified. Curcumenol and epicurzerenone were the primary constituents of
127 HF and EF, whereas curcumenol and 2,4-Dispironorbonylcyclobuta-1,3-dione (ketene dimers) were
128 the primary constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown
129 in Figure 1.

130 3.2. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

131 Redocking, or confirming the docking technique between the receptor and the native ligand, is
132 the first step in molecular docking. RMSD 1.03Å is the outcome of the validation procedure. Since the
133 RMSD value is ≤ 2Å the docking procedure can be deemed acceptable, and the RMSD obtained
134 satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native
135 ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E
136 resistor is shown in Figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand
137 against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (Figure
138 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.




Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS





Figure 2. 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before and red = after redocking)

151 The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89
 152 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and
 153 vemuravnib is still better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity
 154 between the receptor and ligand was higher and the vice versa, the greater the binding affinity value,
 155 the affinity between receptors and the ligands is getting lower [5], [22]. All three compounds do not
 156 bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP
 157 A:594 [22]. The amino acid residues that were shown to interact with ligands displays in Table 1 and
 158 illustrates the interaction between ligands and the BRAF-V600E receptor using 2D visualization
 159 displays in Figure 2.

160 **Table 1.** Molecular interactions present in the selected complex ligands and BRAF V600E receptor and the amino
 161 acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/Ki (μM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6.68	12.63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	-6.89	8.96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6.23	27.21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7.42	Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596



176
 177 **Figure 3.** 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one
 178 (A), 4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one (B), Cyclooctenone (C), and Vemuravenib (D)
 179 with BRAF V600E receptor

180 The likelihood that a molecule has the same or superior activity than BRAF V600E increases
 181 with the number of amino acid similarities between the reference chemical and crucial amino acid. GLN
 182 A:530, CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E
 183 receptor. The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549)
 184 as the reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better
 185 binding scores than vemurafe-nib and a decent MolDock score (≥ -158.139) and Rerank score ($\geq -$
 186 118.607) were recognized as possible hits [5].

187 Out of all the compounds, the three identified compounds found by GC-MS were found to
 188 have the smallest binding affinities. The pkCMS online tool was used to further investigate these
 189 compound's pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive
 190 diffusion to ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According
 191 to Lipinski's guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of
 192 less than 5. molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen
 193 bonds < 10 . Cell membranes are more readily penetrated by ligands with molecular weights less than
 194 500 Da than by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil,
 195 and non-polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout
 196 the body and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of
 197 cell membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the
 198 target molecule decreases. Because they are more broadly distributed throughout the body and are kept
 199 in lipid membranes for longer, excessively hydrophobic compounds typically have a high level of
 200 toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less.
 201 Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The
 202 biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor
 203 and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen
 204 bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three
 205 compounds satisfied Lipinski's guidelines.

206 **Table 2.** Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

207
 208 When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET
 209 estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco-2
 210 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug
 211 absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human
 212 intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same
 213 concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion
 214 in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and
 215 biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance.
 216 AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using
 217 bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a
 218 compound's predictive value is greater than 0.90, it is deemed to have high Caco-2 permeability [26]. It

219 has good permeability because the test results showed a value greater than 0.90. When the volume of
 220 distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<-0.15), it is deemed low; when it is greater than 2.81
 221 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In Table 3, all compounds are in the range volume
 222 distribution requirements so that it can be predicted that all these compounds can be distributed evenly
 223 to provide the same concentration as in blood plasma. Based on Table 3, all ligands have good
 224 pharmacokinetic parameter.

225 **Table 3.** Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD ss (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2- propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8- Hexahydrona phthalen-2(3H)-one	1.501	0.344	No	0.112	No	No
Cyclooctenone	1.487	0.136	No	0.213	No	No

226

227 4. CONCLUSION

228 The best potential components exploration of *C. aeruginosa* fraction with the smallest binding
 229 affinity and meet the pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-
 230 one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol);
 231 and vemuravnib is still better as K+ (-10.593,68kcal/mol). All three compounds do not bind to key
 232 amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. All
 233 three compounds have good pharmacokinetic parameter. These results indicate that further
 234 structural development is needed for better activity.

235 **Acknowledgments:** We thank the Education Financial Services Center (Puslapdik) via the
 236 Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the
 237 financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi
 238 Dona for technical support for this research.

239 **Conflicts of interest:** The authors declare no conflict of interest

240 References

- 241 [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci.*
 242 *2021, Vol. 9, Page 63*, vol. 9, no. 4, p. 63, Oct. 2021.
- 243 [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*,
 244 vol. 8, no. 2, pp. 103–110, Aug. 2020.
- 245 [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant
 246 melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- 247 [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF
 248 V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- 249 [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-
 250 yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and
 251 drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- 252 [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia : attributed properties and uses.*
 253 Cambridge: MIT Press, 1980.
- 254 [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent.*
 255 *Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- 256 [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial
 257 activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma*

- 258 *cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct.
259 2017.
- 260 [9] J. Srivilai *et al.*, "Curcuma aeruginosa Roxb. essential oil slows hair-growth and lightens skin in axillae; a
261 randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- 262 [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair
263 Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no.
264 2, pp. 99–106, Feb. 2018.
- 265 [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles
266 and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*,"
267 *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- 268 [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential
269 oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–
270 184, 2018.
- 271 [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-
272 androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*,
273 vol. 83, no. 5, pp. 864–871, 2012.
- 274 [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and
275 sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a
276 hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- 277 [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56,
278 no. 6, pp. 721–725, Dec. 2018.
- 279 [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from
280 *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J.*
281 *Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- 282 [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam
283 rhizome (*Curcuma aeruginosa* Roxb.)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- 284 [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*,
285 vol. 15, no. 1, pp. 1–7, Jun. 2015.
- 286 [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations:
287 cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13,
288 2024.
- 289 [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.),"
290 *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- 291 [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties,
292 Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopiella vielana*
293 Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- 294 [22] Damayanti, C. Cita Rosita Sigit Prsakoeswa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular
295 Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK
296 Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- 297 [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory
298 Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa*
299 Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- 300 [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of
301 *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- 302 [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster
303 drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- 304 [26] Herdini and I. R. Setyawati, "Studi In Silico : Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*)
305 terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*,
306 vol. 33, no. 2, pp. 81–97, 2023.
- 307 [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada *Pericarpium Pala*
308 (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog.*, vol. 14, no. 2, pp. 81–92, 2021.



© 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Original Article

In Silico Study of Compounds Identified in *Curcuma aeruginosa* Roxb Rhizome as BRAF V600E Inhibitors in Melanoma Cancer

Ririn Suharsanti*, Muhammad Ryan Radix Rahardhian, Lia Kusmita

Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang; Central Java, 50192, Indonesia

*Corresponding author: Ririn Suharsanti | Email: ririnsuharsanti@stifar.ac.id

Received: 16 May 2025; Revised: 22 May 2025; Accepted: 02 June 2025; Published: 30 June 2025

Abstract: *Curcuma aeruginosa* Roxb rhizome contains secondary metabolite compounds and plays a role in various activities such as antioxidant, antibacterial, anthelmintic, antiandrogenic, antinociceptive, and anticancer. Anticancer activity that has been reported in *Curcuma aeruginosa* Roxb rhizome is limited to breast and cervical cancer. The purpose of this study was to explore the potential of *Curcuma aeruginosa* Roxb rhizome in melanoma cancer through the mechanism of inhibiting the BRAF V600E. The 96% ethanol extract of *Curcuma aeruginosa* Roxb rhizome was separated to produce n-hexane (HF), ethyl acetate (EAF), and ethanol (EF) fractions. The GC-MS results showed that there were 31 compounds from the three fractions. The docking validation process was carried out on the native ligand N-(3-[[5-(4-chlorophenyl)-1H-pyrrolo [2,3b]pyridin3yl] carbonyl]2,4-difluorophenyl) propane-1-sulfonamide. All compounds were prepared as ligands for molecular docking with the BRAF V600E receptor (PDB ID: 3OG7). Docking validation on native ligand showed RMSD 1.03Å. The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68 kcal/mol); Cyclooctenone (-6,23 kcal/mol); and vemuravni is still better as K⁺ (-11.11 kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. These results indicate that further structural development is needed for better activity.

Keywords: *Curcuma aeruginosa*; GC-MS ; In Silico, BRAF V600E inhibitor, Vemuravenib

1. INTRODUCTION

Over the past 50 years, melanoma incidence has steadily climbed globally. Melanoma is more prevalent in lower latitudes and among white-skinned individuals. Melanoma is the most common cancer in teenagers and young adults, but it is often more prevalent in the elderly population. In 2020, melanoma of the skin is expected to account for 1.7% of all cancer diagnoses worldwide, with an estimated 325,000 new cases [1]. Vemurafenib and dabrafenib are BRAF mutation-inhibiting chemotherapy drugs to treat melanoma [2], [3]. Approximately 50% of cutaneous melanoma patients have active BRAF V600 mutations, so selective inhibitors were developed. Vemurafenib is responsive in 50% of patients with BRAF V600 mutations and is longer progression-free than dacarbazine (DTIC). In previous research, the reticuline compound in soursop leaves was proven to have the potential to treat cancer through the BRAF V600E inhibitor mechanism in silico [4]. In addition, in silico evaluation of several 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors was carried out [5]. There are several active compounds as BRAF V 300E inhibitors, which provide an opportunity for other natural ingredients to have the same activity.

Traditionally, the *C. aeruginosa* rhizome has been used medicinally to treat stomach ache, obesity and rheumatism, asthma and cough, scurvy and mental disorders [6]. Essential oil content has been identified from the results of the distillation of *C. aeruginosa* Roxb. rhizomes such as curzerenone (24.6%), 1,scineole (11.0%), camphor (10.6%), zedoarol (6.3%), isocurcumenol (5.8%), curcumenol (5.6%) and filranogermenone (5.5%) [7]. Other identified compounds include champor (29,39%) dan germacrone (21,21%) [8], monoterpen (21,47%) berupa β-pinen dan 1,8 cineol [9], 1,8-

cineol (22.65%) dan germacrone (17.70%) [10], tropolene (18,1%) dan eucalyptol (17,9%) [11], β -pinene (21.9%), neocurdione (16.1%) and curcumol (15.2%) [12]. Meanwhile, the compounds that were successfully separated from the black turmeric extract using chromatography include germacrone, zederone, dehydrocurdione, curcumenol, zedoarondiol dan isocurcumenol [13]; dehydrocurdione, curcumenol, dan germacrone [14]; Pyrocurzerenone, Dehydrochromolaenin, Curzeone, Linderazulene, Curzerenone, 8, 12 - Epoxy - 1 (10), 4(15), 7, 11 -germacratetraen-6-one [15]; aeruginon and curcumenone [16]; dan flavon [17]. *C. aeruginosa* isolates that have quite potential in various activities are germacrone as antiandrogenic [13], hair growth promoter [14], antinociceptive [18], and anticancer [16]. Anticancer activity that has been reported in *C. aeruginosa* Roxb rhizome is limited to breast cancer (MCF-7 and T-47D) and cervical cancer (Ca Ski and HeLa S3) [19], [20]. There have been no reports of *C. aeruginosa* being tested for BRAF V600E inhibitory activity as an anti-melanoma cancer in silico so that it is worthy of being processed.

2. MATERIALS AND METHODS

2.1. Chemical

Ethanol, methanol, n-hexane, and ethyl acetate as solvents from Smart Lab, Indonesia. All reagents used for the research were of analytical grade.

2.2. Plant Collection

C. aeruginosa Roxb dried rhizome from the Center for Research and Development of Traditional Medicinal Plants and Medicines Tawangmangu, Central Java, harvested in February 2020.

2.3. Instrumentation

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm.

2.4. Software and Hardware

The Protein Databank (PDB, www.rcsb.org) provided PDB ID: 3OG7 for download [4], [21]. The natural chemical's 3D structure files were obtained from PubChem (www.pubchem.ncbi.nlm.nih.gov). Ligands made with chemdraw 3D 15.0 for molecular docking. AutoDock Tool 1.5.6 Sep_17_14 employed the molecular docking procedure for in-silico screening, and Biovia Discovery Studio V21.1.0.2.20298 was used to view the results. Using a Lenovo laptop running Windows 10 with a Core i3 CPU, 4 GB of RAM, 64-bit operating system, and an x-64 processor, pharmacokinetics and toxicity prediction are performed. The online SMILES Translator (<https://cactus.nci.nih.gov>) was used to translate the compound into SMILES format. To forecast pharmacokinetics and chemical toxicity, the SMILES-formatted molecule was processed using the pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) [22].

2.5. Extraction and Fractination

One kg of the powdered material was macerated for three days at a ratio of 1:5 using 70% ethanol. Ethanol extract (EE) was obtained by combining the filtrates and drying them out using a revolving vacuum evaporator set at 60 °C and 100 rpm. Then, using solvents ranging from non-polar (n-hexane), semi-polar (ethyl acetate), and polar (ethanol), the ethanol extract (EE) was separated by sequential fractination to provide n-hexane (FH), ethyl acetate (EAF), and ethanol (EF). By turning the vacuum evaporator at 60 °C and 100 rpm, respectively, fractions were concentrated [23], [24].

2.6. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

GCMS analysis was carried out in GCMS (Shimadzu QP 2010 SE) and mass spectrophotometer. The columns used are Rtx-5MS (5% diphenyl/95% dimethyl polysiloxane) and Carbowax (Polyethylene glycol), thickness 0.25um, length: 30.0m, inside diameter: 0.25mm. The mobile phase used is helium and was adjusted to a column velocity flow of 0.74 mL/min. Other GC-

MS conditions are ion-source temperature, 250 °C; interface temperature, 300 °C; pressure, 42,3 kPa; and 1 µl injector in split mode with a split ratio of 153.0 with injection temperature of 300 °C. The temperature was raised to 320 °C at the rate of 10 °C/min and held for 5 min. The total elution was 24 min.

2.7. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Protein and ligand preparation is the initial stage of molecular docking. AutoDock Tools-1.5.6 was used to carry out 3D interaction, docking, and binding investigations. The Protein Data Bank provided the target proteins for download (PDB ID: 3OG7) [4], [21]. The Biovia Discovery Studio visualizer program is used to extract native ligands and water molecules from 3D structures to create protein files (.pdb). Chemdraw 3D 15.0 was used to produce the test ligand file (.sdf), which was retrieved from PubChem, for molecular docking. The ligand contributes charge and torsion after the receptor adds charge prior to molecular docking. The grid box's dimensions and coordinates were established. X: 2.643, Y: -2.28, Z: -19.403, and spacing are the grid box coordinates, and the grid box size is 44 × 40 × 40 Å, spacing 0.375. Molecular docking parameters include interacting amino acid residues and binding affinity (kcal/mol). Interaction 2D and 3D between ligand and protein were visualized using Biovia Discover Studio visualizer. The following chemical properties were predicted and explained: polar surface activity (PSA), hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), the number of atom-to-atom bonds that can rotate (Torson), the logarithm of the coefficient octanol/water partition (Log P), and molecular weight (MW). These were conducted utilizing Lipinski's rule of five, a set of guidelines that aids in distinguishing between molecules that resemble drugs and those that do not, using the pkCMS web tool application [5], [21], [25]. This approach might forecast the higher probability of success or failure because of drug penetration and absorption. Following the 3D drawing of the chemical structure using Chemdraw 3D 15.0 and its saving in a particular format (.pdb), the online SMILES Translator (<https://cactus.nci.nih.gov>) was used to convert it to SMILES format. The pkCMS online tool (<https://biosig.lab.uq.edu.au/pkcms>) was used to process the SMILES formatted compound in order to forecast chemical toxicity and pharmacokinetics [22].

3. RESULTS AND DISCUSSION

3.1. Fraction Compounds

According to the GC-MS data, HF was primarily composed of sesquiterpenes (63.1%) and diterpenes (5.26%), with 31.58% of it being unknown substances. The EF was made up of sesquiterpenes (68.42%) and others (31.58%), whereas the EAF was made up of sesquiterpenes (42.86%), diterpenes (21.43%), steroids (7.14%), and others (28.57%). Saturated fatty acids were present when IF was identified. Curcumenol and epicurzerenone were the primary constituents of HF and EF, whereas curcumenol and 2,4-Dispironorbonylcyclobuta-1,3-dione (ketene dimers) were the primary constituents of EAF. All compounds detected from the *C. aeruginosa* fraction are shown in Figure 1.

3.2. Molecular Docking Studies, Pharmacokinetics, and Toxicity Prediction of Chemical Constituents

Redocking, or confirming the docking technique between the receptor and the native ligand, is the first step in molecular docking. RMSD 1.03Å is the outcome of the validation procedure. Since the RMSD value is ≤ 2Å the docking procedure can be deemed acceptable, and the RMSD obtained satisfies the validation acceptance criterion [22]. To show the stance before and after docking, native ligands are shown in two distinct colors. Native ligand in the redocking process with the BRAF V600E receptor is shown in Figure 2. Vemurafenib, a commercial medication, was utilized as a control ligand against the BRAF V600E receptor (PDB ID: 3OG7), while all substances discovered by GC-MS (Figure 1) were used as test ligands. ligand preparation is the initial stage of molecular docking.




Figure 1. Compound Name and Structure Identification of *C. aeruginosa* Fractions Using GC-MS




Figure 2. 3D diagram for the interaction of native ligand with BRAF-V600E receptor (yellow =before and red = after redocking)

The smallest binding affinity are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnib is still better as K+ (-10.593,68kcal/mol). The smaller binding affinity value, the affinity between the receptor and ligand was higher and the vice versa, the greater the binding affinity value, the affinity between receptors and the ligands is getting lower [5], [22]. All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594 [22]. The amino acid residues that were shown to interact with ligands displays in Table 1 and illustrates the interaction between ligands and the BRAF-V600E receptor using 2D visualization displays in Figure 2.

Table 1. Molecular interactions present in the selected complex ligands and BRAF V600E receptor and the amino acids involved.

Complex	Binding Energy (kcal/mol)	Inhibition Constant/Ki (µM)	Amino acid residues
1-Cyclohexyl-2-propen-1-one	-6.68	12.63	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one	-6.89	8.96	Arg 575, Asp 576, Leu 577, Lys 578, Ser 616, Trp 619, Met 620, Ala 621, Val 626, Tyr 633, Ser 637, Asp 638, Ala 641
Cyclooctenone	-6.23	27.21	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641
Vemuravenib	-11.11	7.42	Arg 575, Asp 576, Leu 577, Trp 619, Met 620, Ala 621, Val 624, Tyr 633, Ser 637, Asp 638, Ala 641 Ile-463, Val-471, Ala- 481, Lys-483, Leu-505, Leu-514, Phe-516, Ile-527, Thr-529, Gln-530 , Trp-531, Cys-532 , Ser-535, Ser-536, His-539, Phe-583, Asp-594 , Asp-593, Phe-595, Gly-596




Figure 3. 2D Visualization of Complex Interactions Between Ligands 1-Cyclohexyl-2-propen-1-one (A), 4,4a,5,6,7,8-Hexahydrona phthalen-2(3H)-one (B), Cyclooctenone (C), and Vemuravenib (D) with BRAF V600E receptor

The likelihood that a molecule has the same or superior activity than BRAF V600E increases with the number of amino acid similarities between the reference chemical and crucial amino acid. GLN A:530, CYS A:532, ASP A:594, and THR A:529 are important amino acids linked to the BRAF V600E receptor. The reticuline compound has the same hydrogen-bonded amino acids (GLN 530 and ASP 549) as the reference compound Vemurafenib/key amino acids [22]. Conversely, compounds that had better binding scores than vemurafenib and a decent MolDock score (≥ -158.139) and Rerank score (≥ -118.607) were recognized as possible hits [5].

Out of all the compounds, the three identified compounds found by GC-MS were found to have the smallest binding affinities. The pkCMS online tool was used to further investigate these compound's pharmacokinetic and toxicity characteristics (ADMET). The Lipinski test uses passive diffusion to ascertain whether a substance in cell membranes is hydrophobic or hydrophilic. According to Lipinski's guidelines, a ligand must have a molecular weight of less than 500 Da and a LogP value of less than 5. molar refractivity between 40 and 130, donor hydrogen bonds < 5 , and acceptor hydrogen bonds < 10 . Cell membranes are more readily penetrated by ligands with molecular weights less than 500 Da than by those with molecular weights greater than 500 Da. The polarity of the ligand in fat, oil, and non-polar solvents is correlated with the logP value. Ligands that are widely dispersed throughout the body and have a log P value greater than 5 will interact more readily via the lipid bilayer layer of cell membranes. As a result, the ligand becomes more hazardous and its sensitivity to binding to the target molecule decreases. Because they are more broadly distributed throughout the body and are kept in lipid membranes for longer, excessively hydrophobic compounds typically have a high level of toxicity. The ligand is hydrophobic and has a tendency to dissolve in water when the log P value is less. Since the ligand cannot cross the lipid bilayer membrane, its Log P value cannot be negative. The biological activity of a ligand or medicine is correlated with the amount of hydrogen bonds in the donor and acceptor. The amount of energy needed for absorption increases with the strength of the hydrogen bond [25]. Table 2 displays the outcomes of the molecular docking studies, which showed that the three compounds satisfied Lipinski's guidelines.

Table 2. Ligand's Lipinski Rules of Five

Complex	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar surface activity (PSA)
1-Cyclohexyl-2-propen-1-one	138.21	2.3218	0	1	62.125
4,4a,5,6,7,8-Hexahydrophthalen-2(3H)-one	150.221	2.4659	0	1	67.484
Cyclooctenone	124.183	2.0758	0	1	55.760

When evaluating the pharmacokinetics of novel pharmacological compounds, ADMET estimates are essential. If a compound's anticipated value is more than 0.09, it has significant Caco-2 permeability. Human colorectal cancer epithelial cells are known as Caco-2 cells. To estimate oral drug absorption, Caco-2 cell monolayers are frequently employed as an in vitro model of the human intestinal mucosa. The volume needed for a drug to be uniformly distributed and produce the same concentration as in blood plasma is known as the Steady State Volume of Distribution (VD_{ss}). Excretion in log (ml/min/kg) is predicted by total clearance (CL_{tot}). Hepatic clearance (liver metabolism and biliary clearance) and renal clearance (renal excretion) are the two primary parts of drug clearance. AMES toxicity is frequently used to evaluate a compound's capacity to cause mutagenesis using bacteria. Positive findings suggest that the substance is mutagenic and carcinogenic [22]. If a compound's predictive value is greater than 0.90, it is deemed to have high Caco-2 permeability [26]. It

has good permeability because the test results showed a value greater than 0.90. When the volume of distribution (VD_{ss}) is less than 0.71 L/kg (log VD_{ss}<-0.15), it is deemed low; when it is greater than 2.81 L/kg (log VD_{ss}>0.45), it is deemed excessive [27]. In Table 3, all compounds are in the range volume distribution requirements so that it can be predicted that all these compounds can be distributed evenly to provide the same concentration as in blood plasma. Based on Table 3, all ligands have good pharmacokinetic parameter.

Table 3. Pharmacokinetics (ADMET) Parameters of Ligands

Complex	Absorption Caco2 permeability	Distribution VD _{ss} (human)	Metabolism (CYP2D6 substrate)	Excretion (Total Clearance)	AMES toxicity	Hepato toxicity
1-Cyclohexyl-2-propen-1-one	1.085	0.148	No	0.221	No	No
4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one	1.501	0.344	No	0.112	No	No
Cyclooctenone	1.487	0.136	No	0.213	No	No

4. CONCLUSION

The best potential components exploration of *C. aeruginosa* fraction with the smallest binding affinity and meet the pharmacokinetic requirements are 4,4a,5,6,7,8-Hexahydronaphthalen-2(3H)-one (-6,89 kcal/mol); 1-Cyclohexyl-2-propen-1-one (-6,68kcal/mol); Cyclooctenone (-6,23kcal/mol); and vemuravnib is still better as K⁺ (-10.593,68kcal/mol). All three compounds do not bind to key amino acid residues of BRAF V600E such as vemuravenib at GLN A:530, CYS A:532; ASP A:594. All three compounds have good pharmacokinetic parameter. These results indicate that further structural development is needed for better activity.

Acknowledgments: We thank the Education Financial Services Center (Puslapdik) via the Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan (LPDP)) for the financial support in 2021. We also would like to thank Aulia Isra, Anindya Meipura, and Dwindi Dona for technical support for this research.

Conflicts of interest: The authors declare no conflict of interest

References

- [1] K. Saginala, A. Barsouk, J. S. Aluru, P. Rawla, and A. Barsouk, "Epidemiology of Melanoma," *Med. Sci.* 2021, Vol. 9, Page 63, vol. 9, no. 4, p. 63, Oct. 2021.
- [2] M. A. Syakir and D. I. Anggraini, "Terapi Imunologi Pada Melanoma," *JIMKI J. Ilm. Mhs. Kedokt. Indones.*, vol. 8, no. 2, pp. 103–110, Aug. 2020.
- [3] G. Bollag *et al.*, "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma," *Nature*, vol. 467, no. 7315, pp. 596–599, Sep. 2010.
- [4] A. R. Dewayani *et al.*, "Studi In Silico Senyawa Daun Sirsak (*Annona muricata* L.) Sebagai Inhibitor BRAF V600E Pada Kanker Melanoma," *J. Farm. Udayana*, vol. 11, no. 2, pp. 80–88, 2023.
- [5] A. B. Umar, A. Uzairu, G. A. Shallangwa, and S. Uba, "In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions," *Futur. J. Pharm. Sci.*, vol. 6, no. 1, pp. 1–10, 2020.
- [6] L. Perry and J. Metzger, *Medicinal plants of East and Southeast Asia : attributed properties and uses*. Cambridge: MIT Press, 1980.
- [7] H. M. Sirat, S. Jamil, and J. Hussain, "Essential oil of *Curcuma aeruginosa* roxb. From Malaysia," *J. Essent. Oil Res.*, vol. 10, no. 4, pp. 453–458, 1998.
- [8] N. Akarchariya, S. Sirilun, J. Julsrigival, and S. Chansakaowa, "Chemical profiling and antimicrobial activity of essential oil from *Curcuma aeruginosa* Roxb., *Curcuma glans* K. Larsen & J. Mood and *Curcuma*

- cf. xanthorrhiza* Roxb. collected in Thailand," *Asian Pac. J. Trop. Biomed.*, vol. 7, no. 10, pp. 881–885, Oct. 2017.
- [9] J. Srivilai *et al.*, "Curcuma aeruginosa Roxb. essential oil slows hair-growth and lightens skin in axillae; a randomised, double blinded trial," *Phytomedicine*, vol. 25, pp. 29–38, Feb. 2017.
- [10] J. Srivilai *et al.*, "Sesquiterpene-Enriched Extract of *Curcuma aeruginosa* Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study," *Skin Pharmacol. Physiol.*, vol. 31, no. 2, pp. 99–106, Feb. 2018.
- [11] R. Fitria, D. S. H. Seno, B. P. Priosoeryanto, Hartanti, and W. Nurcholis, "Volatile compound profiles and cytotoxicity in essential oils from rhizome of *Curcuma aeruginosa* and *Curcuma zanthorrhiza*," *Biodiversitas*, vol. 20, no. 10, pp. 2943–2948, Oct. 2019.
- [12] T. O. Pham, T. T. Nguyen, T. X. Do, T. H. Le, N. A. Opeyemi, and A. O. Isiaka, "The rhizome essential oil of *Curcuma aeruginosa* Roxb. (Zingiberaceae) from Vietnam," *Trends Phytochem.*, vol. 2, no. 3, pp. 179–184, 2018.
- [13] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, "Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of *Curcuma aeruginosa* Roxb.," *Fitoterapia*, vol. 83, no. 5, pp. 864–871, 2012.
- [14] J. Srivilai, N. Waranuch, A. Tangsumranjit, N. Khorana, and K. Ingkaninan, "Germacrone and sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a hair growth promoter," *Drug Deliv. Transl. Res.*, vol. 8, no. 1, pp. 140–149, Feb. 2018.
- [15] P. Boutsada *et al.*, "Sesquiterpenoids from the rhizomes of *Curcuma aeruginosa*," *Vietnam J. Chem.*, vol. 56, no. 6, pp. 721–725, Dec. 2018.
- [16] S. Atun, R. Arianingrum, N. Aznam, and S. N. A. Malek, "Isolation of sesquiterpenes lactone from *Curcuma aeruginosa* rhizome and the cytotoxic activity against human cancer cell lines," *Int. J. Pharmacogn. Phytochem. Res.*, vol. 8, no. 7, pp. 1168–1172, 2016.
- [17] B. Hastuti, S. Ibrahim, and M. Efdi, "Isolation structure and elucidation of flavone from Temu Hitam rhizome (*Curcuma aeruginosa* Roxb.)," *J. Chem. Pharm. Res.*, vol. 8, no. 5, pp. 302–304, 2016.
- [18] C. F. Hossain *et al.*, "Antinociceptive principle from *Curcuma aeruginosa*," *BMC Complement. Altern. Med.*, vol. 15, no. 1, pp. 1–7, Jun. 2015.
- [19] P. Panyajai *et al.*, "Anticancer activity of *Curcuma aeruginosa* essential oil and its nano-formulations: cytotoxicity, apoptosis and cell migration effects," *BMC Complement. Med. Ther.*, vol. 24, no. 1, pp. 1–13, 2024.
- [20] A. P. Sari and U. Supratman, "Phytochemistry and Biological Activities of *Curcuma aeruginosa* (Roxb.)," *Indones. J. Chem.*, vol. 22, no. 2, pp. 576–598, Mar. 2022.
- [21] S. S. Ul Hassan *et al.*, "A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from *Xylopiella vielana* Targeting B-Raf Kinase," *Molecules*, vol. 27, no. 3, p. 917, Feb. 2022.
- [22] Damayanti, C. Cita Rosita Sigit Prsakoeswa, D. Purwanto, A. Endaryanto, and Siswandono, "Molecular Docking, Pharmacokinetics, and Toxicity Prediction of Epigallocatechin-3-Gallate (EGCG) on IKK Receptor in Photoaging Prevention," *Indian J. Forensic Med. Toxicol.*, vol. 14, no. 2, pp. 1467–1472, 2020.
- [23] R. Suharsanti, S. Wahyuono, N. Yuniarti, and P. Astuti, "Molecular Docking of Lipase Inhibitory Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa* Roxb Rhizome," *Int. J. Pharm. Res. Appl.*, vol. 9, no. 2, pp. 162–174, 2024.
- [24] S. Wahyuono, N. Yuniarti, and P. Astuti, "Antioxidant Activity and Pancreatic Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions," *J. Biodjati*, vol. 9, no. November, pp. 228–243, 2024.
- [25] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, "Evaluation of blockbuster drugs under the rule-of-five," *Pharmazie*, vol. 65, no. 2, pp. 148–152, 2010.
- [26] Herdini and I. R. Setyawati, "Studi In Silico : Senyawa Aktif Akar Senggugu (*Clerodendrum serratum*) terhadap Penghambatan Reseptor Human Chitotriosidase-1 (hCHIT1) sebagai Antiasma," *Sainstech*, vol. 33, no. 2, pp. 81–97, 2023.
- [27] S. S. Abdullah *et al.*, "Analisis Sifat Fisikokimia, Farmakokinetik dan Toksikologi Pada Pericarpium Pala (*Myristica fragrans*) Secara Artificial Intelligence," *Chem. Prog*, vol. 14, no. 2, pp. 81–92, 2021.

